On Tuesday, a promoter entity of Ajanta Pharma, the Ravi Agrawal Trust, executed a block deal selling shares worth over ₹1,024 crore. The transaction involved the sale of 34.5 lakh shares at a price of ₹2,968 per share. The buyers, Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund, acquired 21.02 lakh and 13.48 lakh shares, respectively. Ajanta Pharma is recognized for its strong performance in therapeutic areas such as ophthalmology and cardiology, and it has been expanding its international presence. The company reported positive fourth-quarter results, with revenue and EBITDA surpassing analyst estimates by 1-3%, and a 23% increase in profit after tax, driven by higher other income and a lower tax rate. The US generics segment showed robust growth, rising 47% year-on-year in USD terms. Elara Capital has raised its core earnings estimates for FY27E-FY28E by 2% and set a target price of ₹3,115 based on a projected 29.9x FY28E core P/E. However, geopolitical disruptions and rising raw material costs pose risks to the company's performance.